Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sameera, Govindaraju"'
Autor:
Ali T. Taher, Yasser Wali, Maria Cecilia Cruz, Pimlak Charoenkwan, Yesim Aydinok, Olena Werner, Sameera Govindaraju, Fabian Romen, Vip Viprakasit
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron
Externí odkaz:
https://doaj.org/article/3ac9ea4995e4411f82eb7796e45ca40e
Publikováno v:
Journal of Biostatistics and Epidemiology, Vol 2, Iss 4 (2017)
Background & Aim: In multivariate receiver operating characteristic (MROC) curve analysis, comparing two tests is usually done by means of area under the curve (AUC’s) and sensitivities. However, the existing procedures have not addressed the issue
Externí odkaz:
https://doaj.org/article/bce3e065e8f540d980e845b5430aa89d
Autor:
Yong‐Rong Lai, Maria Domenica Cappellini, Yesim Aydinok, John Porter, Zeynep Karakas, Vip Viprakasit, Noppadol Siritanaratkul, Antonis Kattamis, Rongrong Liu, Miguel Izquierdo, Janet Lasher, Sameera Govindaraju, Ali Taher
[No Abstract Available]
Novartis Pharmaceuticals Corporation
This study was sponsored and funded by Novartis Pharmaceuticals Corporation.
Novartis Pharmaceuticals Corporation
This study was sponsored and funded by Novartis Pharmaceuticals Corporation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9e03417e409465326795ebed716d31
https://hdl.handle.net/11454/75864
https://hdl.handle.net/11454/75864
Autor:
Udvardy, Miklos, Vladimir, Strugov, Catharina, Lewerin, Sebastian, Grosicki, Grzegorz, Mazur, Michael, Steurer, Marco, Montillo, Irina, Kryachok, Jan M, Middeke, Grygoriy, Rekhtman, Tommaso, Stefanelli, Ghislaine, Vincent, Sameera, Govindaraju, Anders, Österborg
Publikováno v:
British journal of haematologyReferences. 189(4)
In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician's choice. The five-year follow-up